Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Tuesday Ahead of Consumer Confidence Data, US Treasury Buyback Announcement
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Catalyst Pharma's FIRDAPSE Approved in Japan for Rare Autoimmune Disorder Lambert-Eaton Myasthenic Syndrome ("LEMS")
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Is a Favorite Amongst Institutional Investors Who Own 75%
High Growth Tech Stocks In The United States You Should Know